Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma-associated antigen B18 (MAGEB18)
- Target
- MAGEB18
- Molecular classification
- Other (Cancer-testis antigen), Ubiquitin ligase cofactor/regulatory protein
01
Overview
Melanoma-associated antigen B18 (MAGEB18) is a cancer-testis antigen and member of the type I MAGE protein family, encoded on the X chromosome and primarily expressed in testis under normal conditions, but aberrantly upregulated in various tumors including melanoma. MAGEB18 is proposed to play a regulatory role in ubiquitination by binding to RING-type E3 ubiquitin ligases (such as LNX1), potentially modulating their substrate specificity or ligase activity and thus impacting protein stability, signaling pathways, and tumorigenesis. As with other members of the MAGE family, altered expression of MAGEB18 may be associated with poor clinical prognosis in cancers and is being studied as a potential immunotherapy target and biomarker.
- Other names
- MAGE family member B18MAGEB18MGC33889MAGE-B18 antigenmelanoma-associated antigen B18melanoma antigen family B, 18melanoma antigen family B18
02
Mechanism of action
Proposed modulation/enhancement of E3 ubiquitin ligase activity, particularly RING-type zinc finger-containing E3 ligases
03
Biological functions
Regulation of protein ubiquitinationProtein-protein interaction with E3 RING ubiquitin-protein ligasesPotential role in cell proliferationRole in cancer progression
04
Disease associations
Cancer (notably implicated in melanoma and potentially other tumors)
05
Safety considerations
Tumor-specific expression may limit off-target effects, but therapeutic targeting could impact normal testicular or placental tissue
06
Biomarkers
Overexpression/aberrant expression may serve as a cancer biomarker, including for melanoma
Beyond the preview
Go deeper on Melanoma-associated antigen B18 (MAGEB18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma-associated antigen B18 (MAGEB18).